Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity ; volume:13 ; number:1 ; day:28 ; month:11 ; year:2023 ; pages:1-12 ; date:12.2023
Scientific reports ; 13, Heft 1 (28.11.2023), 1-12, 12.2023
- Urheber
-
Quddos, Fatima
Hubshman, Zachary
Tegge, Allison
Sane, Daniel
Marti, Erin
Kablinger, Anita S.
Gatchalian, Kirstin M.
Kelly, Amber L.
DiFeliceantonio, Alexandra G.
Bickel, Warren K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-48267-2
- URN
-
urn:nbn:de:101:1-2024021511190633844310
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Quddos, Fatima
- Hubshman, Zachary
- Tegge, Allison
- Sane, Daniel
- Marti, Erin
- Kablinger, Anita S.
- Gatchalian, Kirstin M.
- Kelly, Amber L.
- DiFeliceantonio, Alexandra G.
- Bickel, Warren K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Temporal patterns of alcohol consumption and attempts to reduce alcohol intake in England
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial